The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosisFlexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivoIntegrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancerThe Wnt-dependent signaling pathways as target in oncology drug discoveryRRx-001, A novel dinitroazetidine radiosensitizerBcl-2 antagonists: a proof of concept for CLL therapyLY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft modelsThymidylate synthase pharmacogenetics.Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancerPopulation pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patientsPomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across MatrigelTopical henna for capecitabine induced hand-foot syndromePhase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinomaPharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogsComparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumorsAn extended phase II trial of ifosfamide plus mesna in malignant mesotheliomaClinical use of thymidine as a rescue agent from methotrexate toxicityClinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B reportClinical toxicity associated with tiazofurin4'-EPI-doxorubicin in advanced lung cancer. A phase II trialPyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusionDisposition of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in miceIfosfamide and mesna in the treatment of malignant disease mesna as urothelial protectorSecond-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genesPhase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.Cdc25 as a potential target of anticancer agents.A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinomaClinical trial design in biosimilar drug development.Phase I trial of vinflunine and pemetrexed in refractory solid tumors.Noninvasive methods to study drug distribution.Inhibition of MDR1 activity and induction of apoptosis by analogues of nifedipine and diltiazem: an in vitro analysis.A novel high-through-put assay for screening of pro-apoptotic drugs.Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study.A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.Human leukocyte alpha interferon-induced transient neurotoxicity in children.Oral topoisomerase 1 inhibitors in adult patients: present and future.Development of multidrug-resistance convertors: sense or nonsense?
P1433
Q22061955-F6E69A23-D72E-4578-9C40-429BB0998BA7Q24314412-D82D351B-8522-42C9-B151-EF2BCCEE080DQ24630174-83644157-69FF-4A72-9D88-384DD169C835Q24652979-F6C0E63F-D003-48C0-BEEF-69DB3791D255Q26769671-C29ADC02-FD07-4A91-A46A-2E5D038A881EQ26823996-270C295D-2B88-43EA-A6ED-70D7E9B90AEDQ27675641-5D3C8044-F66C-41C7-96C0-126E0D9B9FAAQ27863339-98C53139-C3BA-49CA-9F3D-01510D002A6EQ28212508-5682204A-3709-4210-B319-8BF02ADEEEBDQ28237341-F5850F61-F243-4966-A020-27D6FD09887DQ28237865-7845D767-693A-4C2A-B88C-016ED6350DE1Q28250089-82146167-1F57-402D-BF5D-B03DB323BA3EQ28263016-0375B088-610C-4EE7-A445-B5E390F56536Q28283281-C38BBB62-260F-4F31-842E-69A4B84036A2Q28317221-5B6335A6-A6ED-4D83-9D38-BAC40CEA5516Q28318141-34B4481D-D6B4-4883-9D09-5765D35B6524Q28326722-A44F0538-6FAE-4EFA-89A5-EAB2E7950B84Q28330610-750D8D5E-B460-479A-9AD0-8C3B0C69ABF7Q28331161-AE6C006E-2867-45DA-9006-7D7C4D1AFC3FQ28334086-2B6966FE-F9C5-4F27-8D04-4296C4B36D5FQ28335131-F37430C8-DD7C-4A98-89F3-39C7CA7E4596Q28341307-1682619F-7671-4B79-8407-E938100108B4Q28341314-C89B4479-E3BE-45C8-A55C-216567E8C5EAQ28574018-BD63D970-D4AB-404E-B874-A93D69D2E09DQ30301304-D09C365C-988B-410C-97EE-B5F75CDD0A7CQ30326904-971028D9-71A0-43B7-B086-0F49E29C08D6Q30412791-B0F8E88C-441F-4564-AF78-75794A4DF3CDQ30423748-4C9D7BB2-80DE-4036-95FD-9A0030F12DADQ30428531-C093DF64-2087-49A2-AEC0-3FAA5940836BQ30815143-93AF8C86-C338-499A-ACAF-9B267A382799Q30877068-F3E4217A-8C4F-488E-BC15-C4F4C4C5F91AQ31105814-2E11482B-308E-4576-8427-8C8DE557B998Q31126033-3284450A-3D08-4550-B7EA-9293C55EB51CQ33153624-C74E6BA1-8358-4D52-AEA9-B841619E8FFDQ33162379-86180F37-E897-49AB-82F0-3D662862056DQ33165699-EF84150D-3F4B-4B37-8598-AD2C9CA44765Q33167422-2B72B85D-9057-41C2-8E9D-3CE9CDC86B70Q33169142-416B7FD8-E940-41FC-B525-4D82A6C3C167Q33180133-387C11FA-F5EE-40A4-AFE6-F87E3FC526A1Q33180943-438A09ED-06DC-4B3A-841B-4C6AF0047593
P1433
description
begutachtete wissenschaftliche Zeitschrift
@de
peer-reviewed scientific journal
@en
revista científica
@es
revue scientifique
@fr
rivista scientifica
@it
vědecký časopis
@cs
wetenschappelijk tijdschrift van Springer Science+Business Media
@nl
рецензований науковий журнал
@uk
वैज्ञानिक पत्रिका
@hi
name
Investigational New Drugs
@ast
Investigational New Drugs
@da
Investigational New Drugs
@de
Investigational New Drugs
@en
Investigational New Drugs
@es
Investigational New Drugs
@fi
Investigational New Drugs
@fr
Investigational New Drugs
@it
Investigational New Drugs
@nb
Investigational New Drugs
@nl
type
label
Investigational New Drugs
@ast
Investigational New Drugs
@da
Investigational New Drugs
@de
Investigational New Drugs
@en
Investigational New Drugs
@es
Investigational New Drugs
@fi
Investigational New Drugs
@fr
Investigational New Drugs
@it
Investigational New Drugs
@nb
Investigational New Drugs
@nl
prefLabel
Investigational New Drugs
@ast
Investigational New Drugs
@da
Investigational New Drugs
@de
Investigational New Drugs
@en
Investigational New Drugs
@es
Investigational New Drugs
@fi
Investigational New Drugs
@fr
Investigational New Drugs
@it
Investigational New Drugs
@nb
Investigational New Drugs
@nl
P3181
P1055
P1058
P1156
P1250
P1277
P1476
Investigational New Drugs
@en
P236
P3181
P407
P571
1983-01-01T00:00:00Z